International Stem Cell Corporation (OTCBB:ISCOE) announced today that
Kenneth Aldrich, Chairman, will present to investors as part of the
Lippert/Heilshorn & Associates Life Sciences & Medical Technologies
Virtual Conference on Thursday, June 16, 2011 at 10:30 a.m. Eastern.
A webcast of the presentation will be accessible online at www.internationalstemcell.com,
or the PrecisionIR event site: www.vcall.com/CustomEvent/lipper/index.asp.
An archived version will be available for 30 days.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic
applications of human parthenogenetic stem cells and the development and
commercialization of cell-based research and cosmetic products. ISCO's
core technology, parthenogenesis, results in the creation of pluripotent
human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical
issues associated with the use or destruction of viable human embryos.
ISCO scientists have created the first parthenogenic, homozygous stem
cell line that can be a source of therapeutic cells with minimal immune
rejection after transplantation into hundreds of millions of individuals
of differing genders, ages and racial background. This offers the
potential to create the first true stem cell bank, UniStemCell™. ISCO
also produces and markets specialized cells and growth media for
therapeutic research worldwide through its subsidiary Lifeline Cell
Technology, and cell-based skin care products through its subsidiary
Lifeline Skin Care. More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click
on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
International Stem Cell Corporation Kenneth
C Aldrich, Chairman 760-940-6383 kaldrich@intlstemcell.com or Lippert/Heilshorn
& Associates Don Markley 310-691-7100 dmarkley@lhai.com |